阿德福韦酯联合安络化纤丸治疗慢性乙肝失代偿期肝硬化疗效观察

Adefovir dipivoxil and anluohuaxian capsule treatment for decompensated cirrhosis due to chronic hepatitis B

目的研究阿德福韦酯联合安络化纤丸对慢性乙型肝炎引起的失代偿期肝硬化抗病毒及抗纤维化治疗的效果。方法50例患者按1:1的比例随机分配到治疗组及对照组,两组均给予支持治疗,治疗组加用阿德福韦酯和安络化纤丸口服,疗程52周。结果治疗52周末Child-Pugh评分治疗组由10.4±2.3下降为6.2±2.4,对照组由10.3±2.2上升为10.6±1.9,t=7.042P<0.01;HBVDNA转阴率比较,治疗组58.33%,对照组8.33%,χ2=13.5,P<0.01;均存在差异且有统计学意义。结论阿德福韦酯联合安络化纤丸对慢性乙型肝炎引起的失代偿期肝硬化能显著地控制病毒复制,改善肝功能,降低Child-Pugh评分。

Objective The aim of this study was to evaluate the eficacy of adefovir dipivoxil and anluohuaxian capsule treatment for decompensated cirrhosis due to chronic hepatitis B. Methods 48 patients with decompensated cirrhosis of hepatitis B virus infection were were classified into treated group and controls. All patients were given supportive treatment and symptomatic treatment. The treated group were treated with adefovir dipivoxil and anluohuaxian capsule for 52 weeks. Results After 52 weeks, the Child-Pugh score of the treated was decreased from 10. 4 ± 2. 3 to 6. 2 ± 2.4, the control group was increased from 10. 3 ± 2. 2 to 10. 6 ± 1.9,t =7. 042 P 〈0. 01 ; The virologic response rates were 58. 33% and 8. 33% ,Х^2 = 13.5 ,P 〈0. 01 ,the difference has prominent significance. Conclusion Adefovir dipivoxil and anluohuaxian capsule can inhibit HBV replication rapid in decompensated cirrhosis patients due to hepatitis B, resulting in an improvement in liver function and a decrease in Child-Pugh scrre.